Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.32 |
| ▸ | CCNK | O75909 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.32 |
| ▸ | IL1B | P01584 | 3/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970024 | 1.00 | MAPK3 (0.38) | MAPK3TSHRCCNT1CCNKCCNE1 | |
| SCHEMBL19970021 | 1.00 | MAPK3 (0.38) | MAPK3TSHRCCNT1CCNKCCNE1 | |
| SCHEMBL19970087 | 0.95 | CCNT1 (0.35) | MAPK3TSHRCCNT1CCNKCCNE1 | |
| SCHEMBL23770784 | 0.91 | SYK (0.38) | TSHRCCNT1IL1BEPHX2SYK | |
| SCHEMBL23770573 | 0.90 | CCNT1 (0.36) | TSHRCCNT1CCNKCCNE1CDK2 | |
| SCHEMBL19951403 | 0.90 | MAPK3 (0.44) | MAPK3TSHRCCNT1CCNKCCNE1 | |
| SCHEMBL23770706 | 0.87 | SMN1; SMN2 (0.36) | TSHRCCNT1CCNKCCNE1CDK2 | |
| SCHEMBL23770790 | 0.85 | IL1B (0.32) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL23770848 | 0.84 | IL1B (0.33) | IL1BTNF | |
| SCHEMBL22323177 | 0.83 | MAPK3 (0.38) | MAPK3TSHRCCNT1CCNKCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | MAPK3 3255/4885TSHR 1749/4885CCNT1 4170/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | MAPK3 3255/4885TSHR 1749/4885CCNT1 4170/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | MAPK3 3255/4885TSHR 1749/4885CCNT1 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.